Volkan Turan1, Giuliano Bedoschi, Fred Moy, Kutluk Oktay. 1. Innovation Institute for Fertility Preservation, New York, New York; Laboratory of Molecular Reproduction and Fertility Preservation, Obstetrics and Gynecology, New York Medical College, Valhalla, New York.
Abstract
OBJECTIVE: To investigate the safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole protocol for fertility preservation in breast cancer patients. DESIGN: Retrospective cohort study. SETTING: Academic fertility preservation center. PATIENT(S): Seventy-eight women ≤ 45 years, diagnosed with stage ≤ 3 breast cancer, who desired fertility preservation. INTERVENTION(S): Two consecutive cycles versus a single ovarian stimulation cycle with a letrozole-follicle-stimulating hormone (FSH) protocol. MAIN OUTCOME MEASURE(S): Embryo or oocyte cryopreservation outcomes, time interval from surgery to chemotherapy, and breast cancer recurrence rates. RESULT(S): Sixty-one patients underwent single-cycle stimulation and 17 received two stimulation cycles. The mean total number of oocytes harvested (16.1 ± 13.2 vs. 9.1 ± 5.2) and embryos generated (6.4 ± 2.9 vs. 3.7 ± 3.1) were statistically significantly higher in patients who underwent two cycles versus one cycle. The time interval from surgery to chemotherapy was similar between the two-cycle and single-cycle groups (63.7 ± 7.7 vs. 58.0 ± 12.1 days). After a mean follow-up interval of 58.5 ± 13.6 months, the recurrence rates were similar between the two-cycle (0 of 17) and single-cycle (2 of 49) patients. CONCLUSION(S): It appears to be safe and feasible to perform two consecutive ovarian stimulation cycles to increase the oocyte/embryo yield for fertility preservation.
OBJECTIVE: To investigate the safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole protocol for fertility preservation in breast cancerpatients. DESIGN: Retrospective cohort study. SETTING: Academic fertility preservation center. PATIENT(S): Seventy-eight women ≤ 45 years, diagnosed with stage ≤ 3 breast cancer, who desired fertility preservation. INTERVENTION(S): Two consecutive cycles versus a single ovarian stimulation cycle with a letrozole-follicle-stimulating hormone (FSH) protocol. MAIN OUTCOME MEASURE(S): Embryo or oocyte cryopreservation outcomes, time interval from surgery to chemotherapy, and breast cancer recurrence rates. RESULT(S): Sixty-one patients underwent single-cycle stimulation and 17 received two stimulation cycles. The mean total number of oocytes harvested (16.1 ± 13.2 vs. 9.1 ± 5.2) and embryos generated (6.4 ± 2.9 vs. 3.7 ± 3.1) were statistically significantly higher in patients who underwent two cycles versus one cycle. The time interval from surgery to chemotherapy was similar between the two-cycle and single-cycle groups (63.7 ± 7.7 vs. 58.0 ± 12.1 days). After a mean follow-up interval of 58.5 ± 13.6 months, the recurrence rates were similar between the two-cycle (0 of 17) and single-cycle (2 of 49) patients. CONCLUSION(S): It appears to be safe and feasible to perform two consecutive ovarian stimulation cycles to increase the oocyte/embryo yield for fertility preservation.
Authors: Gwendolyn P Quinn; Susan T Vadaparampil; Ji-Hyun Lee; Paul B Jacobsen; Gerold Bepler; Johnathan Lancaster; David L Keefe; Terrance L Albrecht Journal: J Clin Oncol Date: 2009-10-13 Impact factor: 44.544
Authors: J-H Dalle; G Lucchini; A Balduzzi; M Ifversen; K Jahnukainen; K T Macklon; A Ahler; A Jarisch; M Ansari; E Beohou; D Bresters; S Corbacioglu; A Dalissier; C Diaz de Heredia Rubio; T Diesch; B Gibson; T Klingebiel; A Lankester; A Lawitschka; R Moffat; C Peters; C Poirot; N Saenger; P Sedlacek; E Trigoso; K Vettenranta; J Wachowiak; A Willasch; M von Wolff; I Yaniv; A Yesilipek; P Bader Journal: Bone Marrow Transplant Date: 2017-03-13 Impact factor: 5.483
Authors: Joceline V Vu; Natalia C Llarena; Samantha L Estevez; Molly B Moravek; Jacqueline S Jeruss Journal: J Surg Oncol Date: 2016-12-14 Impact factor: 3.454